GlobeStar Therapeutics Corporation (OTCBB: GSTC) has made notable advancements in its drug development for Multiple Sclerosis, as highlighted in its recent 8K filing. The company emphasizes its commitment to improving treatments for neurodegenerative diseases, revealing that over 4 million individuals are diagnosed with Multiple Sclerosis annually in the U.S. The management asserts that the patented solution could significantly impact patients' lives. GlobeStar is on a determined path to seek FDA approval for its therapy.
Summary not available.
GlobeStar Therapeutics Corporation (OTC PINK:GSTC) has partnered with the Washington Football Team Yearbook producers for inclusion in their 2021-2022 guide, showcasing their brand and offerings. This partnership aims to increase visibility among NFL fans as part of their rebranding initiative following their name change. The company also plans to launch a new website on July 21, 2021, featuring a health library focused on Multiple Sclerosis and neurodegenerative diseases. GlobeStar is committed to providing effective healthcare solutions and raising awareness about the challenges associated with these conditions.
GlobeStar Therapeutics Corporation (formerly AngioSoma, OTC PINK:SOAN) has received FINRA approval for its name change effective immediately as of July 6, 2021. The company shifts focus towards medical research and treatments, particularly for neurodegenerative diseases like Multiple Sclerosis. A new CUSIP number (37960P104) will be issued, and a new website is set to launch soon, featuring an expanded health library. CEO James C. Katzaroff expressed enthusiasm for the name change, emphasizing the company's commitment to growth in healthcare.